Association of PDE11A Global Haplotype with Major Depression and Antidepressant Drug Response

Total Page:16

File Type:pdf, Size:1020Kb

Association of PDE11A Global Haplotype with Major Depression and Antidepressant Drug Response ORIGINAL RESEARCH Association of PDE11A global haplotype with major depression and antidepressant drug response Huai-Rong Luo Abstract: Cyclic nucleotide phosphodiesterases (PDEs) hydrolyze the intracellular second Gui-Sheng Wu messengers cAMP and cGMP to their corresponding monophosphates. PDEs play an important Chuanhui Dong role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Mauricio Arcos-Burgos We have previously shown that the individual haplotype GAACC in the PDE11A gene was Luciana Ribeiro associated with major depressive disorder (MDD) based on block-by-block analysis. There are Julio Licinio two PDE genes, PDE11A and PDE1A, located in chromosome 2q31–q32. In this study, we have further explored whether the whole region 2q31–q32 contribute to MDD or antidepressant Ma-Li Wong response 278 depressed Mexican-American participants and 321 matched healthy controls. Center on Pharmacogenomics, Although there is no signifi cant interaction between the two genes, the remission rate of individual Department of Psychiatry and Behavioral Science, University carrying the combination genotype at rs1880916 (AG/AA) and rs1549870 (GG) is signifi cantly of Miami Miller School of Medicine, increased. We analyzed the global haplotype by examining 16 single-nucleotide polymorphisms Miami, FL, USA (SNPs) in PDE11A and six SNPs in PDE1A. None of the haplotypes consisting of six SNPs in the PDE1A have a signifi cant difference between depressed and control groups. Among haplotypes consisting of 16 SNPs across 440 kb in the PDE11A gene, 18 common haplotypes (with frequency higher than 0.8%) have been found in the studied population. Six haplotypes showed signifi cantly different frequencies between the MDD group and the control group. The phylogenetic network result for the 16 SNPs showed that several historic recombination events have happened in the PDE11A gene. The frequency of one haplotype is signifi cantly lower in the remitter group than in the nonremitter group for the depressed participants treated with either desipramine or fl uoxetine. Thus, our data suggest that the PDE11A global haplotype is associated with both MDD and antidepressant drug response. Keywords: PDE11A, major depression, antidepressant, haplotype, linkage disequilibrium, recombination Introduction The 3', 5'-cyclic nucleotides cAMP and cGMP function as second messengers in a wide variety of signal transduction pathways. 3', 5'-cyclic nucleotide phosphodies- terases (PDEs) catalyze the hydrolysis of cAMP and cGMP to the corresponding 5’-monophosphates and provide a mechanism to downregulate cAMP- and cGMP- signaling. Human PDEs are composed of 21 genes and are categorized into 11 families based on sequence homology, enzymatic properties, and sensitivity to inhibitors.1–3 Correspondence: Ma-Li Wong PDE11A gene is the most recently identifi ed and cloned member of the PDE Professor and Vice-Chair for Translational 4 Research, Director of Center protein superfamily. Four N-terminal transcript variants (PDE11A1, A2, A3, and A4) on Pharmacogenomics, Department encoding different isoforms have been found for this gene.5,6 The PDE11A1, A2, and of Psychiatry and Behavioral Sciences, University of Miami Miller School A3 have a catalytic domain and an N-terminus GAF domain, while the full-length of Medicine, Batchelor Children’s form, PDE11A4, contains two GAF domains and a catalytic domain.4–7 The GAF Research Institute, 1580 NW 10th Avenue, Room 633-A, Miami, domain in PDE11A is homologous to other signaling molecule as found in PDE2, FL 33136, USA PDE5, PDE6, and PDE10.1–3,8 The GAF domain is involved in high affi nity allosteric + Tel 1 305 243 4727 cGMP and other small signaling molecules binding. Because of their unique ligand- Fax +1 305 2439708 Email [email protected] binding topologies, the GAF domains of PDEs are likely to offer good new targets Neuropsychiatric Disease and Treatment 2009:5 163–170 163 © 2009 Luo et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Luo et al for rational drug design.9 PDE11A exhibits properties of of Ն18 with item number 1 (depressed mood) rated Ն2. dual-substrate PDE and hydrolyzes both cAMP and cGMP Detailed inclusion and exclusion criteria for both control 4–6 12,13,15 into AMP and GMP respectively with similar Km values. and depressed participants were described previously. The Km for cAMP and cGMP were similar for all the four We used diagnostic and ratings instruments that have been PDE11A variants.4–6 fully validated in English and Spanish, and all assessments Haplotypes provide a record of evolution history more were conducted in the participants’ primary language. All accurately than individual single-nucleotide polymorphisms Mexican-American participants aged 21–68 years had at (SNPs), they can also capture linkage disequilibrium (LD) least three grandparents born in Mexico. Written informed and recombination hotspots information of a genomic region consent was obtained from each participant. more completely. Individual haplotype results detected by All patients had an initial comprehensive psychiatric haplotype blocks may vary considerably from different and medical assessment and, if enrolled, had nine weeks of algorithms since the methods for block defi nition are still structured follow up assessments. The study consisted of under devising and no single approach is appropriate for two phases: a 1-week single-blind placebo lead-in phase to all datasets.10 If a recombination hotspot occurs within one minimize the impact of placebo responders followed, if par- gene, using this gene as candidate may not be appropriate. ticipants continue to meet the inclusion criteria after phase 1, An alternative to individual haplotype association study is by random assignment to one of the two treatment groups: to perform multimarker association analysis with multiple fl uoxetine 10–40 mg/day or desipramine 50–200 mg/day, adjacent markers,11 that is global haplotype. In unrelated indi- administered in a double-blind manner for eight weeks, viduals, PHASE program has been widely used to infer the with blind dose escalation based on clinical outcomes. In the most likely haplotype that an individual has inherited.11 Since depressed group, 230 participants received treatment in our we previously demonstrated a signifi cant association between double-blind clinical trial. Of those, 143 patients completed an individual haplotype in the PDE11A gene and major the study, 61 attained remission, defi ned as having a fi nal depressive disorder (MDD),12 and two PDE genes (PDE11A HAM-D21 score of Ͻ8, and the remainder (n = 82) were and PDE1A) are located in chromosome 2q31–q32, we now categorized as nonremitters. evaluate if the whole region 2q31–q32 is associated with MDD by analyzing the gene–gene interaction. Combinations Genotype procedure of the individual haplotypes in multiple loci might determine The Illumina human SNP linkage analysis platform (Illumina, the complexity of an individual’s susceptibility for MDD and San Diego, CA) was used for genotyping.16,17 Briefl y, all outcome of antidepressant treatment. Therefore, we aimed to genomic DNAs were quantitated using PicoGreen and do the haplotype phasing before block partition using PHASE diluted into 100 ng/μl concentration. Then, the DNAs were software by examining 16 SNPs across the PDE11A and six transferred into seven bar-coded plastic 96-well conical SNPs on the PDE1A gene in this study. microtiter plates. Genotyping of 27 SNPs on the PDE1A and PDE11A genes was done at the Wellcome Trust Sanger Materials and methods Institute (Hinxton, UK) using the Golden Gate assay Participants (Illumina) and following the manufacturers’ instruction.16 This study was approved by the IRBs of the University of All genotypes were evaluated using a quantitative quality California Los Angeles and the University of Miami, and it score called GenCall score. A GenCall score ranges from has been registered in ClinicalTrials.gov (NCT00265292). 0 to 1 and refl ects the proximity within a cluster plot of the Genomic DNA samples from 599 Mexican-Americans were intensities of that genotype to the centroid of the nearest used in this study: 278 depressed participants enrolled in a cluster. Poorly performing samples were removed from the pharmacogenetic study of antidepressant treatment response genotyping report fi les, and individual genotypes with Gen- to desipramine or fl uoxetine, and 321 age- and sex-matched Call scores below 0.25 were assigned a nocall. Data quality control participants recruited from the same Mexican-American was assessed by duplicate DNAs (n = 26) across all plates. community in Los Angeles.12,13 Controls were in general Genotypes from nonmatching duplicates were dropped; they good health but were not screened for medical or psychiatric were also dropped if they had one missing data point. Devia- illness. Inclusion criteria included DSM-IV diagnosis of a tion from Hardy–Weinberg equilibrium (HWE) was tested current unipolar major depressive episode, with a 21-item separately for the control and depressed groups by using the Hamilton Depression Rating Scale (HAM-D21) score14 ALLELE procedure in SAS/Genetics 9.1.3 (SAS Institute, 164 Neuropsychiatric Disease and Treatment 2009:5 PDE11A haplotype associated with major depression and drug response Cary, NC). SNPs that were not in HWE in the control group population stratifi cation in our data.18
Recommended publications
  • RNA Sequencing Reveals Novel Transcripts from Sympathetic
    www.nature.com/scientificreports OPEN RNA Sequencing Reveals Novel Transcripts from Sympathetic Stellate Ganglia During Cardiac Received: 8 January 2018 Accepted: 15 May 2018 Sympathetic Hyperactivity Published: xx xx xxxx Emma N. Bardsley 1, Harvey Davis 1, Olujimi A. Ajijola2, Keith J. Buckler1, Jefrey L. Ardell2, Kalyanam Shivkumar 2 & David J. Paterson 1 Cardiovascular disease is the most prevalent age-related illness worldwide, causing approximately 15 million deaths every year. Hypertension is central in determining cardiovascular risk and is a strong predictive indicator of morbidity and mortality; however, there remains an unmet clinical need for disease-modifying and prophylactic interventions. Enhanced sympathetic activity is a well-established contributor to the pathophysiology of hypertension, however the cellular and molecular changes that increase sympathetic neurotransmission are not known. The aim of this study was to identify key changes in the transcriptome in normotensive and spontaneously hypertensive rats. We validated 15 of our top-scoring genes using qRT-PCR, and network and enrichment analyses suggest that glutamatergic signalling plays a key role in modulating Ca2+ balance within these ganglia. Additionally, phosphodiesterase activity was found to be altered in stellates obtained from the hypertensive rat, suggesting that impaired cyclic nucleotide signalling may contribute to disturbed Ca2+ homeostasis and sympathetic hyperactivity in hypertension. We have also confrmed the presence of these transcripts in human donor stellate samples, suggesting that key genes coupled to neurotransmission are conserved. The data described here may provide novel targets for future interventions aimed at treating sympathetic hyperactivity associated with cardiovascular disease and other dysautonomias. Sympathetic hyperactivity is a key feature of human hypertension that is also seen in animal models of cardio- vascular disease1,2.
    [Show full text]
  • Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham a Thesis Submitted in Conformity
    Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Molecular Genetics University of Toronto © Copyright by Edward James Higginbotham 2020 i Abstract Characterizing Genomic Duplication in Autism Spectrum Disorder Edward James Higginbotham Master of Science Graduate Department of Molecular Genetics University of Toronto 2020 Duplication, the gain of additional copies of genomic material relative to its ancestral diploid state is yet to achieve full appreciation for its role in human traits and disease. Challenges include accurately genotyping, annotating, and characterizing the properties of duplications, and resolving duplication mechanisms. Whole genome sequencing, in principle, should enable accurate detection of duplications in a single experiment. This thesis makes use of the technology to catalogue disease relevant duplications in the genomes of 2,739 individuals with Autism Spectrum Disorder (ASD) who enrolled in the Autism Speaks MSSNG Project. Fine-mapping the breakpoint junctions of 259 ASD-relevant duplications identified 34 (13.1%) variants with complex genomic structures as well as tandem (193/259, 74.5%) and NAHR- mediated (6/259, 2.3%) duplications. As whole genome sequencing-based studies expand in scale and reach, a continued focus on generating high-quality, standardized duplication data will be prerequisite to addressing their associated biological mechanisms. ii Acknowledgements I thank Dr. Stephen Scherer for his leadership par excellence, his generosity, and for giving me a chance. I am grateful for his investment and the opportunities afforded me, from which I have learned and benefited. I would next thank Drs.
    [Show full text]
  • Dissecting the Genetics of Human Communication
    DISSECTING THE GENETICS OF HUMAN COMMUNICATION: INSIGHTS INTO SPEECH, LANGUAGE, AND READING by HEATHER ASHLEY VOSS-HOYNES Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Epidemiology and Biostatistics CASE WESTERN RESERVE UNIVERSITY January 2017 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We herby approve the dissertation of Heather Ashely Voss-Hoynes Candidate for the degree of Doctor of Philosophy*. Committee Chair Sudha K. Iyengar Committee Member William Bush Committee Member Barbara Lewis Committee Member Catherine Stein Date of Defense July 13, 2016 *We also certify that written approval has been obtained for any proprietary material contained therein Table of Contents List of Tables 3 List of Figures 5 Acknowledgements 7 List of Abbreviations 9 Abstract 10 CHAPTER 1: Introduction and Specific Aims 12 CHAPTER 2: Review of speech sound disorders: epidemiology, quantitative components, and genetics 15 1. Basic Epidemiology 15 2. Endophenotypes of Speech Sound Disorders 17 3. Evidence for Genetic Basis Of Speech Sound Disorders 22 4. Genetic Studies of Speech Sound Disorders 23 5. Limitations of Previous Studies 32 CHAPTER 3: Methods 33 1. Phenotype Data 33 2. Tests For Quantitative Traits 36 4. Analytical Methods 42 CHAPTER 4: Aim I- Genome Wide Association Study 49 1. Introduction 49 2. Methods 49 3. Sample 50 5. Statistical Procedures 53 6. Results 53 8. Discussion 71 CHAPTER 5: Accounting for comorbid conditions 84 1. Introduction 84 2. Methods 86 3. Results 87 4. Discussion 105 CHAPTER 6: Hypothesis driven pathway analysis 111 1. Introduction 111 2. Methods 112 3. Results 116 4.
    [Show full text]
  • Gnomad Lof Supplement
    1 gnomAD supplement gnomAD supplement 1 Data processing 4 Alignment and read processing 4 Variant Calling 4 Coverage information 5 Data processing 5 Sample QC 7 Hard filters 7 Supplementary Table 1 | Sample counts before and after hard and release filters 8 Supplementary Table 2 | Counts by data type and hard filter 9 Platform imputation for exomes 9 Supplementary Table 3 | Exome platform assignments 10 Supplementary Table 4 | Confusion matrix for exome samples with Known platform labels 11 Relatedness filters 11 Supplementary Table 5 | Pair counts by degree of relatedness 12 Supplementary Table 6 | Sample counts by relatedness status 13 Population and subpopulation inference 13 Supplementary Figure 1 | Continental ancestry principal components. 14 Supplementary Table 7 | Population and subpopulation counts 16 Population- and platform-specific filters 16 Supplementary Table 8 | Summary of outliers per population and platform grouping 17 Finalizing samples in the gnomAD v2.1 release 18 Supplementary Table 9 | Sample counts by filtering stage 18 Supplementary Table 10 | Sample counts for genomes and exomes in gnomAD subsets 19 Variant QC 20 Hard filters 20 Random Forest model 20 Features 21 Supplementary Table 11 | Features used in final random forest model 21 Training 22 Supplementary Table 12 | Random forest training examples 22 Evaluation and threshold selection 22 Final variant counts 24 Supplementary Table 13 | Variant counts by filtering status 25 Comparison of whole-exome and whole-genome coverage in coding regions 25 Variant annotation 30 Frequency and context annotation 30 2 Functional annotation 31 Supplementary Table 14 | Variants observed by category in 125,748 exomes 32 Supplementary Figure 5 | Percent observed by methylation.
    [Show full text]
  • Incorporating Tandem Duplications Into Ortholog Assignment Based on Genome Rearrangement Guanqun Shi1*, Liqing Zhang2, Tao Jiang1
    Shi et al. BMC Bioinformatics 2010, 11:10 http://www.biomedcentral.com/1471-2105/11/10 METHODOLOGY ARTICLE Open Access MSOAR 2.0: Incorporating tandem duplications into ortholog assignment based on genome rearrangement Guanqun Shi1*, Liqing Zhang2, Tao Jiang1 Abstract Background: Ortholog assignment is a critical and fundamental problem in comparative genomics, since orthologs are considered to be functional counterparts in different species and can be used to infer molecular functions of one species from those of other species. MSOAR is a recently developed high-throughput system for assigning one-to-one orthologs between closely related species on a genome scale. It attempts to reconstruct the evolutionary history of input genomes in terms of genome rearrangement and gene duplication events. It assumes that a gene duplication event inserts a duplicated gene into the genome of interest at a random location (i.e., the random duplication model). However, in practice, biologists believe that genes are often duplicated by tandem duplications, where a duplicated gene is located next to the original copy (i.e., the tandem duplication model). Results: In this paper, we develop MSOAR 2.0, an improved system for one-to-one ortholog assignment. For a pair of input genomes, the system first focuses on the tandemly duplicated genes of each genome and tries to identify among them those that were duplicated after the speciation (i.e., the so-called inparalogs), using a simple phylogenetic tree reconciliation method. For each such set of tandemly duplicated inparalogs, all but one gene will be deleted from the concerned genome (because they cannot possibly appear in any one-to-one ortholog pairs), and MSOAR is invoked.
    [Show full text]
  • Genome-Wide Dissection of Microrna Functions and Cotargeting Networks Using Gene-Set Signatures
    Genome-wide dissection of microRNA functions and cotargeting networks using gene-set signatures The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Tsang, John S., Margaret S. Ebert, and Alexander van Oudenaarden. “Genome-wide Dissection of MicroRNA Functions and Cotargeting Networks Using Gene Set Signatures.” Molecular Cell 38.1 (2010): 140–153. As Published http://dx.doi.org/10.1016/j.molcel.2010.03.007 Publisher Elsevier Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/76631 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike 3.0 Detailed Terms http://creativecommons.org/licenses/by-nc-sa/3.0/ NIH Public Access Author Manuscript Mol Cell. Author manuscript; available in PMC 2011 June 9. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Mol Cell. 2010 April 9; 38(1): 140±153. doi:10.1016/j.molcel.2010.03.007. Genome-wide dissection of microRNA functions and co- targeting networks using gene-set signatures John S. Tsang1,2, Margaret S. Ebert3,4, and Alexander van Oudenaarden2,3,4 1 Graduate Program in Biophysics, Harvard University, Cambridge, MA 2 Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 3 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 4 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA SUMMARY MicroRNAs are emerging as important regulators of diverse biological processes and pathologies in animals and plants. While hundreds of human miRNAs are known, only a few have known functions.
    [Show full text]
  • Alterations of Phosphodiesterases in Adrenocortical Tumors
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector REVIEW published: 30 August 2016 doi: 10.3389/fendo.2016.00111 Alterations of Phosphodiesterases in Adrenocortical Tumors Fady Hannah-Shmouni†, Fabio R. Faucz and Constantine A. Stratakis* Program on Developmental Endocrinology and Genetics (PDEGEN), Section on Endocrinology and Genetics (SEGEN), National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA Alterations in the cyclic (c)AMP-dependent signaling pathway have been implicated in the majority of benign adrenocortical tumors (ACTs) causing Cushing syndrome (CS). Phosphodiesterases (PDEs) are enzymes that regulate cyclic nucleotide levels, including cyclic adenosine monophosphate (cAMP). Inactivating mutations and other functional variants in PDE11A and PDE8B, two cAMP-binding PDEs, predispose to ACTs. The involvement of these two genes in ACTs was initially revealed by a genome-wide association study in patients with micronodular bilateral adrenocortical hyperplasia. Thereafter, PDE11A or PDE8B genetic variants have been found in other ACTs, including macronodular adrenocortical hyperplasias and cortisol-producing adenomas. In addi- Edited by: Andre Lacroix, tion, downregulation of PDE11A expression and inactivating variants of the gene have Université de Montréal, Canada been found in hereditary and sporadic testicular germ cell tumors, as well as in prostatic Reviewed by: cancer. PDEs confer an increased risk of ACT formation probably through, primarily, Cristina L. Ronchi, University Hospital of Wuerzburg, their action on cAMP levels, but other actions might be possible. In this report, we Germany review what is known to date about PDE11A and PDE8B and their involvement in the Delphine Vezzosi, predisposition to ACTs.
    [Show full text]
  • Comparing the Intestinal Transcriptome of Meishan And
    Comparing the intestinal transcriptome of Meishan and Large White piglets during late fetal development reveals genes involved in glucose and lipid metabolism and immunity as valuable clues of intestinal maturity Ying Yao, Valentin Voillet, Maëva Jégou, Magali San Cristobal, Samir Dou, Véronique Romé, Yannick Lippi, Yvon Billon, Marie-Christine Pere, Gaëlle Boudry, et al. To cite this version: Ying Yao, Valentin Voillet, Maëva Jégou, Magali San Cristobal, Samir Dou, et al.. Comparing the intestinal transcriptome of Meishan and Large White piglets during late fetal development reveals genes involved in glucose and lipid metabolism and immunity as valuable clues of intestinal maturity. BMC Genomics, BioMed Central, 2017, 18 (1), pp.647. 10.1186/s12864-017-4001-2. hal-01643654 HAL Id: hal-01643654 https://hal.archives-ouvertes.fr/hal-01643654 Submitted on 21 Nov 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Open Archive TOULOUSE Archive Ouverte (OATAO) OATAO is an open
    [Show full text]
  • Detecting Genomic Imprinting and Maternal Effects in Family-Based
    Detecting Genomic Imprinting and Maternal Effects in Family-Based Association Studies Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Fangyuan Zhang, Graduate Program in Biostatistics The Ohio State University 2015 Dissertation Committee: Prof. Shili Lin, Advisor Prof. Haikady N. Nagaraja Prof. Christopher W. Bartlett c Copyright by Fangyuan Zhang 2015 Abstract Genomic imprinting and maternal effects are two important epigenetic factors, that can contribute to phenotypic variation without changing DNA sequence. They are the source of the missing heritability that cannot be explained by genome-wide association studies. Genomic imprinting and maternal effects have been shown to affect many complex human diseases, including Prader-Willi, Beckwith-Weidemann, and Angelman syndromes, and childhood cancers. My dissertation focuses on the detection of these two epigenetic factors in family-based association studies. We first propose a Monte Carlo Pedigree Parental-Asymmetry Test utilizing both Affected and Unaffected offspring (MCPPATu) for detecting imprinting effect. Though genomic imprinting and maternal effects can be confounded, when there is no maternal effect, the proposed method is simple and powerful. It utilizes information from both affected and unaffected offspring and allows for missing genotypes through Monte Carlo sampling. Simulation studies demonstrate that MCPPATu controls the empirical type I error rate well under the null hypotheses of no parent-of-origin effects. It also shows that the use of additional information from unaffected offspring and partially observed genotypes can greatly improve the statistical power. Second part of our work offers a practical strategy to select optimum study design in the detection of genomic imprinting and maternal effect jointly within a case-control ii family scheme.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 09/23/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • UNIVERSITY of CALIFORNIA Los Angeles Identification of Genetic
    UNIVERSITY OF CALIFORNIA Los Angeles Identification of Genetic Etiology in Disorders of Sex Development A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Human Genetics by Hayk Barseghyan 2017 © Copyright by Hayk Barseghyan 2017 ABSTRACT OF THE DISSERTATION Identification of Genetic Etiology in Disorders of Sex Development by Hayk Barseghyan Doctor of Philosophy in Human Genetics University of California, Los Angeles, 2017 Professor Eric J.N. Vilain, Chair Disorders of Sex Development (DSD) are defined as “congenital conditions in which development of chromosomal, gonadal, or anatomic sex is atypical.” These conditions have an approximate frequency of 0.5-1% of live births and encompass a wide variety of urogenital abnormalities ranging from mild hypospadias to sex reversal. Lack of standardized anatomical/endocrine phenotyping and the limited number of known DSD genes with poor genotype/phenotype correlation have hampered the field of clinical management, leaving many patients without a definitive genetic diagnosis. Thus, the focus of this dissertation is to identify the underlying pathogenic genetic mutations that disrupt development of urogenital structures, leading to Disorders of Sex Development in humans. The traditional trend of diagnostic approach for patients with DSD is to select candidate gene testing by searching for additional phenotypic and metabolic information ii through imaging studies and endocrine tests that could explain the patient’s phenotype. This approach is usually ineffective, costly and time-consuming. To address this issue and identify genetic variants leading to DSD, we utilized exome sequencing, in patients diagnosed with abnormal sex development. We show that exome sequencing has transformed the field of clinical genetic diagnosis by increasing the rate of diagnosis by approximately 30% and has become a method of choice for many clinicians.
    [Show full text]
  • Prognostic and Clinicopathological Insights of Phosphodiesterase 9A Gene As Novel Biomarker in Human Colorectal Cancer Tasmina Ferdous Susmi1†, Atikur Rahman1,2†, Md
    Susmi et al. BMC Cancer (2021) 21:577 https://doi.org/10.1186/s12885-021-08332-3 RESEARCH Open Access Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer Tasmina Ferdous Susmi1†, Atikur Rahman1,2†, Md. Moshiur Rahman Khan1, Farzana Yasmin1, Md. Shariful Islam3,4*, Omaima Nasif5, Sulaiman Ali Alharbi6, Gaber El-Saber Batiha7 and Mohammad Uzzal Hossain8 Abstract Background: PDE9A (Phosphodiesterase 9A) plays an important role in proliferation of cells, their differentiation and apoptosis via intracellular cGMP (cyclic guanosine monophosphate) signaling. The expression pattern of PDE9A is associated with diverse tumors and carcinomas. Therefore, PDE9A could be a prospective candidate as a therapeutic target in different types of carcinoma. The study presented here was designed to carry out the prognostic value as a biomarker of PDE9A in Colorectal cancer (CRC). The present study integrated several cancer databases with in-silico techniques to evaluate the cancer prognosis of CRC. Results: The analyses suggested that the expression of PDE9A was significantly down-regulated in CRC tissues than in normal tissues. Moreover, methylation in the DNA promoter region might also manipulate PDE9A gene expression. The Kaplan–Meier curves indicated that high level of expression of PDE9A gene was associated to higher survival in OS, RFS, and DSS in CRC patients. PDE9A demonstrated the highest positive correlation for rectal cancer recurrence with a marker gene CEACAM7. Furtheremore, PDE9A shared consolidated pathways with MAPK14 to induce survival autophagy in CRC cells and showed interaction with GUCY1A2 to drive CRPC. Conclusions: Overall, the prognostic value of PDE9A gene could be used as a potential tumor biomarker for CRC.
    [Show full text]